What happens to Celgene (CELG) if the proposed $74 billion acquisition by Bristol-Myers Squibb (BMY) dies?
“That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on its board are doing everything they can to prevent the deal from unraveling,” said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
why panic,though i have a fair stake in celgene,and welcome the deal,our pipeline ought to suffice for the future.If not,than what is all the hype about Bristol Myers looking toward the future via the celgene pipeline.It the deal goes south,why should Celgene given their future drug prospects.These scare tactics are just short term profit driven behaviors.